Once yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
Here, we developed an immunomodulatory, encapsulated cell–based “biologics factory” that overcomes mAb instability, immunogenicity, and the fibrotic foreign body response that have limited previous approaches, enabling continuous in situ production of therapeutic antibodies from a single administration.
Appeared: Sunday, October 4. Science Advances. Peer-reviewed journal.